Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3857111 | 0.88 | KCNH2 (0.47) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL5331634 | 0.84 | PTGDR2 (0.43) | KCNH2NR1I2SCN5ACYP3A4PTGDR2 | |
| SCHEMBL3706595 | 0.84 | NR1I2 (0.40) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL2637665 | 0.83 | NR1I2 (0.64) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL14253915 | 0.76 | NR1I2 (0.63) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL50642 | 0.73 | KCNH2 (0.61) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL2637667 | 0.73 | NR1I2 (0.47) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL3857114 | 0.73 | NR1I2 (0.40) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 | |
| SCHEMBL3871757 | 0.73 | KMT2A (0.37) | SCN5ACYP3A4CYP2C9CYP2C19SCN9A | |
| SCHEMBL14081119 | 0.72 | NR1I2 (0.68) | KCNH2NR1I2SCN5ACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010099159-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-02 | — | — | WO | disclosed |
| EP-2215095-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2209789-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2209784-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2121697-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2121696-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Brystol-Myers Squibb Company (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2118109-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2118108-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2009-11-18 | — | — | EP | disclosed |
| EP-2114947-A1 | INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | Brystol-Myers Squibb Company (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2099804-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Brystol-Myers Squibb Company (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008112863-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112841-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112848-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008097796-A1 | INDOLOBENZAZEPINE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008089027-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007140200-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140109-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007136982-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |